Eloxx Pharmaceuticals, Inc. Stock Analysis & AI Score
Eloxx Pharmaceuticals, Inc. (ELOX) has an ST Score of 67.9 (B), driven by its Valuation (A) and held back by its Financial Strength (B-). Analysts rate it Buy with a $37.67 price target (+196.6% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AIELOX Stock Price History
ELOX Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
ELOX Latest Stock News
ST Score
Eloxx Pharmaceuticals, Inc. (ELOX) has an ST Score of 67.9 (B), driven by its Valuation (A) and held back by its Financial Strength (B-). Analysts rate it Buy with a $37.67 price target (+196.6% upside).
- Strongest
- ValuationA
- Weakest
- Financial StrengthB-
All factor grades
- ValuationA
- ForecastA
- MomentumA-
- ProfitabilityB+
- GrowthB
- Financial StrengthB-
- Piotroski3/9
Press Releases
Company Contact Details
ELOX stock: frequently asked questions
What is ELOX's ST Score?
Eloxx Pharmaceuticals, Inc. (ELOX) has an ST Score of 67.9 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ELOX a buy, hold, or sell?
Analysts rate ELOX a Buy, with a price target of $37.67 (+196.6% vs the current price). Our ST Score grades it B (67.9/100). The ST Score is a data-driven signal, not a recommendation.
What are ELOX's factor grades?
Valuation A, Profitability B+, Financial Strength B-, Momentum A-, Growth B, Forecast A.
What is ELOX's valuation grade?
Eloxx Pharmaceuticals, Inc. (ELOX) earns a valuation grade of A, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ELOX's growth grade?
Eloxx Pharmaceuticals, Inc. (ELOX) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ELOX's profitability grade?
Eloxx Pharmaceuticals, Inc. (ELOX) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ELOX's financial strength grade?
Eloxx Pharmaceuticals, Inc. (ELOX) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ELOX?
The average analyst price target for Eloxx Pharmaceuticals, Inc. (ELOX) is $37.67 from 12 analysts, which is +196.6% versus the recent price of $12.70.
What is ELOX's Piotroski score?
Eloxx Pharmaceuticals, Inc. (ELOX) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.